We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-12.52%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.5B
AUM Growth
-$1.54B
Cap. Flow
+$155M
Cap. Flow %
1.63%
Top 10 Hldgs %
41.52%
Holding
149
New
17
Increased
43
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$108M
2
CRVS icon
Corvus Pharmaceuticals
CRVS
+$75.4M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$71.1M
4
LLY icon
Eli Lilly
LLY
+$70.2M
5
UNH icon
UnitedHealth
UNH
+$67.9M

Top Sells

Rank Stock Value
1
HNT
HEALTH NET INC
HNT
+$205M
2
VTRS icon
Viatris
VTRS
+$149M
3
AFFX
Affymetrix Inc
AFFX
+$75.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$59.4M
5
BMY icon
Bristol-Myers Squibb
BMY
+$48.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.92%
2 Financials 0.22%
3 Technology 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
26
Ironwood Pharmaceuticals
IRWD
$601M
$126M 1.33%
13,791,178
+386,856
+3% +$3.19M
COO icon
27
Cooper Companies
COO
$14.1B
$123M 1.29%
3,183,600
-476,000
-13% -$16.4M
PFE icon
28
Pfizer
PFE
$143B
$122M 1.29%
4,344,588
-2,108
-0% -$60.2K
NBIX icon
29
Neurocrine Biosciences
NBIX
$18.3B
$105M 1.1%
2,653,874
+138,900
+6% +$5.51M
UNH icon
30
UnitedHealth
UNH
$383B
$105M 1.1%
812,000
+574,000
+241% +$67.9M
RLYP
31
DELISTED
RELYPSA INC COM
RLYP
$100M 1.06%
7,400,000
– –
AGN.PRA
32
DELISTED
Allergan plc
AGN.PRA
$95.8M 1.01%
104,200
– –
ACHN
33
DELISTED
Achillion Pharmaceuticals
ACHN
$88.9M 0.94%
11,519,700
+1,869,800
+19% +$13.7M
ISEE
34
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$88.5M 0.93%
2,094,500
+83,000
+4% +$4.23M
BMRN icon
35
BioMarin Pharmaceuticals
BMRN
$11.9B
$84.4M 0.89%
1,023,200
+874,200
+587% +$71.1M
TSRO
36
DELISTED
TESARO, Inc.
TSRO
$84.2M 0.89%
1,912,000
+147,300
+8% +$5.91M
PBYI icon
37
Puma Biotechnology
PBYI
$403M
$80.9M 0.85%
2,753,425
+514,600
+23% +$23.3M
MNK
38
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$80.2M 0.84%
1,309,000
+47,000
+4% +$3M
CRVS icon
39
Corvus Pharmaceuticals
CRVS
$1.12B
$76.2M 0.8%
+5,258,450
New +$75.4M
INSY
40
DELISTED
Insys Therapeutics, Inc.
INSY
$72.9M 0.77%
4,557,740
+191,000
+4% +$3.63M
NUVA
41
DELISTED
NuVasive, Inc.
NUVA
$72.3M 0.76%
1,487,000
– –
HUM icon
42
Humana
HUM
$43.2B
$62.1M 0.65%
+339,700
New +$58.9M
LOXO
43
DELISTED
Loxo Oncology, Inc
LOXO
$59.5M 0.63%
2,175,857
– –
JNJ icon
44
Johnson & Johnson
JNJ
$640B
$57.5M 0.61%
531,800
+239,800
+82% +$24.8M
IMGN
45
DELISTED
Immunogen Inc
IMGN
$51.9M 0.55%
6,095,647
– –
SHPG
46
DELISTED
Shire pic
SHPG
$51.6M 0.54%
300,371
+49,400
+20% +$8.27M
XBI icon
47
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$50.7M 0.53%
+981,200
New +$51M
MDT icon
48
Medtronic
MDT
$112B
$50M 0.53%
666,299
+78,000
+13% +$5.87M
GKOS icon
49
Glaukos
GKOS
$9.34B
$48.9M 0.51%
2,897,938
+1
+0% +$17
CI icon
50
Cigna
CI
$78.4B
$46M 0.48%
335,500
+53,500
+19% +$7.35M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2016 Portfolio in Review

As of Q1 2016, OrbiMed held 149 positions worth $9.5B, down 14% from $11B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q1 2016 filing shows 17 new, 43 increased, 27 reduced and 8 closed positions. Its largest new stake was Corvus Pharmaceuticals: 5,258,450 shares worth $76.2M. The largest sale was HEALTH NET INC, an estimated $205M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q1 2016 buy was Corvus Pharmaceuticals: 5,258,450 shares worth $76.2M.
  • OrbiMed added most to Vertex Pharmaceuticals in Q1 2016, an estimated $108M increase.
  • OrbiMed's biggest Q1 2016 reduction was Viatris, cutting an estimated $149M.
  • OrbiMed fully exited HEALTH NET INC in Q1 2016, selling an estimated $205M.
  • OrbiMed's ten largest holdings make up 42% of its $9.5B portfolio in Q1 2016.
  • OrbiMed opened 17 new positions and closed 8 in Q1 2016.
  • OrbiMed's portfolio value fell 14% quarter-over-quarter to $9.5B.

Based on OrbiMed's 13F filing for Q1 2016, filed 16 May 2016.